Welcome to our dedicated page for Boston Scien Cp news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scien Cp stock.
Boston Scientific Corporation (NYSE: BSX) is a global medical technology company whose news flow reflects activity across cardiovascular, neuromodulation, urology, endoscopy and other therapeutic areas. Company announcements frequently describe new agreements to acquire medical technology firms, clinical and regulatory milestones for key product platforms, and detailed quarterly financial results.
Recent news includes a definitive agreement to acquire Penumbra, Inc. in a cash and stock transaction. Penumbra has developed mechanical thrombectomy and neurovascular devices to treat conditions such as pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, heart attack and aneurysms, with products like the Lightning Bolt and Lightning Flash computer assisted vacuum thrombectomy systems and peripheral embolization technologies. Boston Scientific has also announced an agreement to acquire Valencia Technologies Corporation, adding the eCoin implantable tibial nerve stimulation system for urge urinary incontinence, and an agreement to acquire Nalu Medical, Inc., developer of the Nalu Neurostimulation System for peripheral nerve stimulation in chronic pain.
In addition to acquisition news, Boston Scientific regularly issues earnings releases detailing net sales by business and region, growth rates on reported, operational and organic bases, and commentary on segment performance in MedSurg and Cardiovascular. These releases often highlight regulatory approvals, such as expanded labeling for the FARAPULSE Pulsed Field Ablation System or CE marks for devices like the WATCHMAN FLX Pro Left Atrial Appendage Closure Device, as well as clinical study results, including long-term data from deep brain stimulation trials.
Investors and observers following BSX news can also expect updates on investor conferences, investor day events, and governance matters disclosed through press releases and Form 8-K filings. This page aggregates such coverage, offering a centralized view of Boston Scientific’s strategic transactions, product developments, financial updates and corporate announcements over time.
Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 37th Annual Strategic Decisions Conference on June 4, 2021. The event will feature a virtual 45-minute Q&A session with key executives including Mike Mahoney, Susie Lisa, and Lauren Tengler, starting at approximately 8:00 a.m. EDT. Investors can access a live webcast on the Boston Scientific Investor Relations website, with a replay available one hour after the event concludes.
Boston Scientific's recent presentation at EuroPCR 2021 highlighted the positive performance of the ACURATE neo2 Aortic Valve System. Data from the Early neo2 and ITAL-neo Registries showed low rates of paravalvular leakage (1.3%) and permanent pacemaker implementation (6%). Additionally, the ACURATE neo2 demonstrated a 56% reduction in aortic regurgitation compared to its predecessor. The device has received CE Mark approval and is currently under evaluation in the U.S. under an IDE trial for patients with aortic stenosis.
Boston Scientific Corporation (NYSE: BSX) announced its participation in two upcoming investor conferences: the 2021 Bank of America Health Care Conference on May 11, 2021, and the 2021 UBS Global Healthcare Virtual Conference on May 25, 2021. Executives including Dan Brennan and Jeff Mirviss will engage in Q&A sessions at both conferences. Live webcasts will be available for investors and can be accessed through the company's investor relations website. This activity reflects Boston Scientific's continued engagement with investors and commitment to transparency.
Boston Scientific reported Q1 2021 net sales of $2.752 billion, an increase of 8.2% year-over-year. GAAP net income rose to $327 million, or $0.23 per share, compared to $11 million, or $0.01 per share, last year. The company exceeded guidance, with adjusted EPS at $0.37 versus the forecasted $0.28 to $0.34. Growth was seen across segments, particularly MedSurg and Cardiovascular, and strong performance in emerging markets at 16%. Regulatory approvals were received for key products, including TheraSphere and Ranger systems.
Boston Scientific Corporation (NYSE: BSX) will host a conference call on April 28, 2021, at 8:00 a.m. EDT to discuss its financial results for the first quarter ending March 31, 2021. The call will be led by Mike Mahoney, CEO, and Dan Brennan, CFO. A news release with the financial results will precede the call on the same day. Additionally, on May 5, 2021, key executives will participate in a Q&A at the Truist Securities 2021 Life Sciences Summit. Webcasts for both events will be available online.
Boston Scientific has announced positive results from the TARGET study of TheraSphere™ Y-90 Glass Microspheres, presented at the Society of Interventional Radiology meeting on March 25, 2021. This therapy aims to treat hepatocellular carcinoma (HCC), the most common liver cancer, showing a median overall survival of 20.3 months. The study reported only 4.8% of patients experienced severe adverse events, indicating safety and tolerability. TheraSphere is the only FDA-approved technology for unresectable HCC, paving the way for optimized treatment protocols.
Boston Scientific Corporation (NYSE: BSX) announced FDA approval for TheraSphere™ Y-90 Glass Microspheres to treat hepatocellular carcinoma (HCC). This approval enhances access to a therapy previously limited under humanitarian device exemptions. HCC is a prevalent cancer, with an estimated 32,000 new U.S. cases in 2021. Results from the LEGACY study demonstrated high response rates and overall survival, with 100% patient response seen after two treatments. The outpatient procedure reduces hospital burdens and aligns with recent NICE recommendations, indicating improved patient outcomes.
Boston Scientific (NYSE: BSX) has signed a definitive agreement to acquire Lumenis LTD.'s global surgical business for $1.07 billion. The deal, expected to close in the second half of 2021, includes Lumenis's innovations in energy-based medical solutions, specifically in urology and otolaryngology. With anticipated 2021 net sales of $200 million, the acquisition aims to enhance Boston Scientific's stone management offerings and expand its market presence in Europe and Asia. The impact on earnings per share is projected to be immaterial in 2021 but accretive starting in 2022.
Boston Scientific Corporation (NYSE: BSX) will participate in two investor conferences: the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, featuring CFO Dan Brennan and VP Susie Lisa, and the Cowen 41st Annual Health Care Conference on March 1, 2021, with SVP Meghan Scanlon and VP Susie Lisa. Each session will include a 30-minute Q&A segment. Live webcasts and replays will be available via the company's investor relations website.
Boston Scientific reported Q4 2020 net sales of $2.708 billion, showing a decline of (6.8)% compared to Q4 2019. GAAP net income available to common stockholders was $138 million or $0.10 EPS, significantly down from $3.996 billion or $2.83 EPS a year prior. For the full year 2020, sales totaled $9.913 billion, down (7.7)%. The transition to a consignment model for WATCHMAN customers impacted results negatively. The company received multiple FDA approvals and is planning growth for 2021 with projected revenue increases of 13% to 19%.
FAQ
What is the current stock price of Boston Scien Cp (BSX)?
What is the market cap of Boston Scien Cp (BSX)?
